SCHEMBL27186134

SCHEMBL27186134

O=C(O)c1cn(C2CCOCC2)c(=O)c2cc[nH]c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD9 Q9H8M2 6/20 0.41
▸ KDM4E B2RXH2 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ JAK2 O60674 2/20 0.37
▸ JAK1 P23458 2/20 0.37
▸ JAK3 P52333 1/20 0.37
▸ TAF1 P21675 5/20 0.36
▸ CECR2 Q9BXF3 4/20 0.36
▸ BRD4 O60885 4/20 0.35
▸ BTK Q06187 1/20 0.34
▸ HCAR1 Q9BXC0 1/20 0.34
▸ KDM4A O75164 1/20 0.34
▸ KDM4C Q9H3R0 1/20 0.34
▸ BRD7 Q9NPI1 2/20 0.33
▸ TRIM24 O15164 1/20 0.33
▸ BRD2 P25440 1/20 0.33
▸ SMARCA4 P51532 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29844397 0.89 BTK (0.41) BRD9JAK2JAK1JAK3TAF1
SCHEMBL27186174 0.86 BRD9 (0.40) BRD9JAK2JAK1JAK3TAF1
SCHEMBL27186376 0.75 SOS1 (0.46) —
SCHEMBL27186378 0.75 SOS1 (0.46) —
SCHEMBL29844104 0.75 SOS1 (0.46) —
SCHEMBL27186231 0.73 KRAS (0.38) BRD9TAF1CECR2
SCHEMBL29168348 0.72 P2RX7 (0.34) KDM4EALDH1A1HPGDHSD17B10BRD4
SCHEMBL30417603 0.69 KDM4E (0.76) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL21246029 0.69 CNR2 (0.39) KDM4EGAA
SCHEMBL30853365 0.68 BTK (0.39) CECR2BRD4BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109887-A1 NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2024-04-04 — — US disclosed
CN-117651701-A Novel substituted bicyclic aza heterocycles as SOS1 inhibitors 唯久生物技术(苏州)有限公司 2024-03-05 — — CN disclosed
WO-2022187266-A1 NOVEL SUBSTITUTED BICYCLI AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2022-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109887-A1 NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS SOS1, SOS2, KSR1 BRD9 907/4885KDM4E 1518/4885ALDH1A1 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback